Johnson & Johnson Stock Forecast: Trending Bullish Among Analysts

Johnson & Johnson (JNJ) stock has risen 49.6% over the past year, though it slipped 2.0% in both the last week and the last month. Wall Street’s analysts are moderately bullish, forecasting further gains with a 12‑month average price target of $252.87 versus the recent close at $237.28.

Analyst Asad Haider of Goldman Sachs & Co. LLC reiterated his Buy rating on JNJ on March 18, 2026, setting a price target of $265.00, which signals more upside from current levels. Haider is a highly rated voice, ranking 1,589 out of 12,068 analysts on TipRanks, with a strong 78.79% success rate and an average return of 21.60% per rating.

Haider’s optimism is driven by the U.S. FDA’s earlier‑than‑expected approval of Icotyde, a first‑in‑class targeted oral IL‑23 receptor agonist for moderate‑to‑severe plaque psoriasis in patients aged 12 and older. This marks the start of a new product cycle for JNJ, where the firm now expects Icotyde to become a meaningful revenue contributor by 2027.

Goldman’s model currently projects Icotyde sales of $200 million in 2026 and $750 million in 2027, already ahead of consensus and with room for upward revisions. JNJ believes Icotyde could ultimately exceed $5 billion in peak non‑risk‑adjusted sales, helped by the appeal of a once‑daily pill in a market still dominated by injectables such as Skyrizi and Tremfya.

Beyond psoriasis, Icotyde is backed by a broad development program in Psoriatic Arthritis, Ulcerative Colitis, and Crohn’s Disease, with several Phase 3 trial milestones slated between 2026 and 2028. Haider argues that this approval underlines JNJ’s ability to advance a strong pipeline into a period of accelerating growth and maintains that JNJ remains one of the best‑positioned names in big pharma. Never miss a stock rating. Find all the latest ratings on TipRanks’ Top Wall Street Analysts page.